|
|
Article: Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men--United States, 2003, and revised recommendations for gonorrhea treatment, 2004.
- Article from:
- MMWR. Morbidity and Mortality Weekly Report
- Article date:
- April 30, 2004
- Author:
CopyrightCOPYRIGHT 2004 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
In the United States, an estimated 700,000-800,000 persons are infected with Neisseria gonorrhoeae each year (1,2). Since 1993, CDC has recommended use of fluoroquinolones (i.e., ciprofloxacin, ofloxacin, or levofloxacin) for gonorrhea treatment. Fluoroquinolone therapy is used frequently because it is an inexpensive, oral, and single-dose therapy. However, because of increased prevalence of fluoroquinolone-resistant N. gonorrhoeae (QRNG) * in Asia, the Pacific Islands (including Hawaii), and California, fluoroquinolones are no longer recommended for treating gonorrhea acquired in those locations (3-5). This report describes increases in QRNG among men who have sex with ...